IGF1 and Alzheimer disease: Overall, the data indicate that brain insulin resistance and altered IGF-1 signaling disrupt the PI3K/AKT pathway, leading to the activation of GSK3β, which in turn promotes tau hyperphosphorylation and AD pathology (Figure 2).